Mouse Anti-PEX16 Recombinant Antibody (3E10) (CBMAB-P1473-YC)

Peroxisomal Biogenesis Factor 16

PEX16 is an integral peroxisomal membrane protein. An inactivating nonsense mutation localized to this gene was observed in a patient with Zellweger syndrome of the complementation group CGD/CG9. Expression of this gene product morphologically and biochemically restores the formation of new peroxisomes, suggesting a role in peroxisome organization and biogenesis. Alternative splicing has been observed for this gene and two variants have been described.

Peroxisomal Biogenesis Factor 16; Peroxisomal Membrane Protein PEX16; Peroxisome Biogenesis Factor 16; Peroxin 16; Peroxin-16; PBD8A; PBD8B;

Required for peroxisome membrane biogenesis. May play a role in early stages of peroxisome assembly. Can recruit other peroxisomal proteins, such as PEX3 and PMP34, to de novo peroxisomes derived from the endoplasmic reticulum (ER). May function as receptor for PEX3.

ER-dependent peroxisome localizationManual Assertion Based On ExperimentIDA:UniProtKB
ER-dependent peroxisome organizationManual Assertion Based On ExperimentIDA:UniProtKB
Peroxisome membrane biogenesisManual Assertion Based On ExperimentIMP:UniProtKB
Peroxisome organizationManual Assertion Based On ExperimentIMP:UniProtKB
Protein import into peroxisome matrixManual Assertion Based On ExperimentIMP:MGI
Protein import into peroxisome membraneManual Assertion Based On ExperimentIMP:UniProtKB
Protein targeting to peroxisomeManual Assertion Based On ExperimentIMP:UniProtKB
Protein to membrane dockingManual Assertion Based On ExperimentIDA:UniProtKB

Peroxisome membrane

Peroxisome biogenesis disorder complementation group 9 (PBD-CG9):
A peroxisomal disorder arising from a failure of protein import into the peroxisomal membrane or matrix. The peroxisome biogenesis disorders (PBD group) are genetically heterogeneous with at least 14 distinct genetic groups as concluded from complementation studies. Include disorders are: Zellweger syndrome (ZWS), neonatal adrenoleukodystrophy (NALD), infantile Refsum disease (IRD), and classical rhizomelic chondrodysplasia punctata (RCDP). ZWS, NALD and IRD are distinct from RCDP and constitute a clinical continuum of overlapping phenotypes known as the Zellweger spectrum (PBD-ZSS).
Peroxisome biogenesis disorder 8A (PBD8A):
A fatal peroxisome biogenesis disorder belonging to the Zellweger disease spectrum and clinically characterized by severe neurologic dysfunction with profound psychomotor retardation, severe hypotonia and neonatal seizures, craniofacial abnormalities, liver dysfunction, and biochemically by the absence of peroxisomes. Additional features include cardiovascular and skeletal defects, renal cysts, ocular abnormalities, and hearing impairment. Most severely affected individuals with the classic form of the disease (classic Zellweger syndrome) die within the first year of life.
Peroxisome biogenesis disorder 8B (PBD8B):
A relatively mild peroxisome biogenesis disorder. Affected individuals manifest lower limb spasticity and ataxia resulting in wheelchair dependence. Other features include optic atrophy, cataracts, dysarthria, dysphagia, constipation, and a peripheral demyelinating motor and sensory neuropathy. Cognition is relatively preserved. Biochemical abnormalities are mild and include increased very-long-chain fatty acids (VLCFA), increased bile acid intermediates, and increased branched chain fatty acids. Phytanic acid alpha-oxidation, pristanic acid beta-oxidation, and red cell plasmalogen are normal.

Cytoplasmic: 1-84
Helical: 85-105
Peroxisomal: 106-110
Helical: 111-131
Cytoplasmic: 132-336